Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
770.880.3%
QQQ
718.600.13%
BTC/USD
79712.491.9238%
DIA
534.500.45%
GLD
406.940.8%
TLT
82.420.43%

Solid Biosciences Inc

SLDBNASDAQ
Trade with Public
Trade with Public
$10.31
-0.11-1.01%
Last update: Sep 4, 12:25 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Solid Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Solid Biosciences (SLDB).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

2S.Buy
13Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$17Upside to Avg. PT+68.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026Cantor FitzgeraldKristen KluskaPT RaiseOverweight$16→$26
Aug 21, 2026Truist SecuritiesDanielle BrillPT RaiseBuy$16→$20
More with Benzinga EdgeGet Access

Analyst Ratings News

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.
Avi Kapoor

PRO
Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26

Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20

Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $16 to $20.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25

HC Wainwright & Co. analyst Arthur He maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $20 to $25.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price Target

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $16 price target.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $16

Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17 to $16.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved